To kick off our Summer Weekend Reads series, Cytel presents “Sufficient Information Threshold for Effective Bayesian Applications: The Effective, Efficient, and Ethical Way Forward” by Cytel’s VP of Customer Success Pantelis Vlachos, VP of Scientific Strategy & Innovation Kyle Wathen, Associate Director of Content Marketing Esha Senchaudhuri, and CSO Yannis Jemiai. Please click below to access the full position paper.
Trial sponsors have spent decades trying to figure out when a clinical trial has achieved enough data to determine its success or futility. The Sufficient Information Threshold describes this conceptual point: that is, when all information relevant to the study has been collected, allowing decision-makers to answer questions about the efficiency, quality, and effectiveness of a clinical study. And there are myriad scientific, rational, and ethical reasons to stop enrolling patients after this threshold is reached: it is unnecessary, it adds little value, it wastes resources, and it can expose patients to subpar treatments.
We know it is critical to approximate this threshold as quickly as possible, but how? Cytel’s East Bayes cloud-powered software can provide important insights using Bayesian methodologies, providing the continuous learning needed to make decisions about the future of a clinical trial.
Click below to learn more about the Sufficient Information Threshold and how Cytel’s products can help capture and leverage this crucial conceptual moment to craft optimal trial designs.
Read more from the Summer Weekend Read series:
If you'd like updates on our Summer Weekend Read series, sign up for email updates below.